Synthesis, characterization and in-vitro antitubercular activity of isoniazid-gelatin conjugate

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 5, 2012, Pages 712-718

  Cassano, Roberta ^a   Trombino, Sonia ^a   Ferrarelli, Teresa ^a   Cavalcanti, Paolina ^b   Giraldi, Cristina ^b   Lai, Francesco ^c   Loy, Giuseppe ^c   Picci, Nevio ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Virology and Microbiology Service of Annunziata Hospital   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

antitubercular activity; gelatin; isoniazid; oxidation; solid phase synthesis

Indexed keywords

DRUG METABOLITE; GELATIN; ISONIAZID; POLYMER; TERT BUTYL HYDROPEROXIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CALORIMETRY; CONTROLLED STUDY; COVALENT BOND; DRUG ABSORPTION; DRUG OXIDATION; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; MACROMOLECULE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROPHOTOMETRY;

ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; GELATIN; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PRODRUGS; SOLID-PHASE SYNTHESIS TECHNIQUES;

EID: 84859599353     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01461.x     Document Type: Article

References (25)

1. Liu S, et al,. Nanosized gold-loaded gelatin/silica nanocapsules. Adv Mater 2005; 17: 1862-1866.
2. Xia W, et al,. Tissue engineering of cartilage with the use of chitosan-gelatin complex scaffolds. J Biomed Mater Res Part B Appl Biomat 2004; 71B: 373-380.
3. Dainiak MB, et al,. Gelatin-fibrinogen cryogel dermal matrices for wound repair: preparation, optimisation and in vitro study. Biomaterials 2010; 31: 67-76.
4. Saraogi GK, et al,. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010; 385: 143-149.
5. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing WHO Report 2006. Geneva: WHO/HTM/TB/2006.362 World Health Organization (WHO), 2006. Available at.
6. Gupta UD, Katoch VM,. Animal models of tuberculosis for vaccine development. Indian J Med Res 2009; 129: 11-19.
7. Du Toit LC, et al,. Tuberculosis chemotherapy: current drug delivery approaches. Resp Res 2006; 7: 1-18.
8. Gelperina S, et al,. The potential advantages of nanoparticles drug delivery systems in chemotherapy of tuberculosis. Am J Resp Crit Care Med 2005; 172: 1487-1490.
9. Deol P, Khuller GK,. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997; 1334: 161-172.
10. Kreuter J,. Nanoparticles as drug delivery system. In:, Nalwa HS, ed. Encyclopedia of Nanoscience and Nanotechnology Vol. 7. New York: American Scientific Publishers, 2004: 161-180.
11. Manca ML, et al,. PLGA, chitosan or chitosan coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization. Coll Surf B Biointer 2008; 62: 220-231.
12. Kumar PV, et al,. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 2006; 14: 546-556.
13. Kreuter J,. Nanoparticles. In:, Kreuter J, ed. Colloidal Drug Delivery Systems Vol. 66. New York: Marcel Dekker, 1994: 219-342.
14. Soppimath KS, et al,. Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Rel 2001; 70: 1-20.
15. Preziosi P,. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8: 839-851.
16. Albericio F, et al,. New trends in peptide coupling reagents. Org Prep Proced Int 2001; 33: 203-303.
17. Sabatino G, et al,. Assessment of new 6-Cl-HOBt based coupling reagents for peptide synthesis. Part 1: Coupling efficiency study. Lett Pept Sci 2009; 9: 119-123.
18. Eidus L, Hamilton EJ,. Screening test for fast isoniazid inactivators. Clin Chem 1964; 10: 581-588.
19. Cassano R, et al,. A novel dextran hydrogel linking trans-ferulic acid for the stabilization and transdermal delivery of vitamin E. Eur J Pharm Biopharm 2009; 72: 232-238.
20. Cassano R, et al,. Synthesis and antioxidant activity evaluation of a novel cellulose hydrogel containing trans-ferulic acid. Carbohyd Polym 2009; 78: 184-188.
21. Siddiqi SH, et al,. Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 1981; 13: 908-912.
22. Li DX, et al,. Novel gelatin micro-capsule with bioavailability enhancement of ibuprofen using spray drying technique. Int J Pharm 2008; 355: 277-284.
23. Vasir JK, et al,. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005; 1: 47-64.
24. Iseman MD,. Tuberculosis therapy: past, present and future. Eur Respir J 2002; 20: 87s-94s.
25. Panickar JR, Hoskyns W,. Treatment failure in tuberculosis. Eur Respir J 2007; 29: 561-564.